Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (Iparomlimab + Tuvonralimab) plus targeted therapy and mFOLFOX6 in first-line treatment for advanced colorectal cancer
ChiCTR2600115908Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in colorectal cancer (CRC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Objective response rate (ORR). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600115908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115908.